From May to now, 8 pharmaceutical enterprises have obtained drug registration approval documents!

[pharmaceutical Station industry trends] driven by the reform of national drug review and approval, the progress of innovative drug approval has been significantly accelerated According to the public announcement of the pharmaceutical industry, the author found that since May, 8 pharmaceutical companies have obtained the approval documents for drug registration, and many products will also enter the sprint period China biopharmaceutical announced on May 22 that the anticoagulant apixaban developed by its subsidiary, Zhengda Tianqing, has obtained the drug registration approval from China food and drug administration, which is applicable to adult patients undergoing hip or knee joint selective replacement to prevent venous thromboembolism Kanghong Pharmaceutical Co., Ltd announced in the evening of May 16 that Kanghong biology, a wholly-owned subsidiary of the company, had received the "drug registration approval document" on conbercept ophthalmic injection issued by the State Food and drug administration Conbercept ophthalmic injection is a class 1 biological innovative drug independently developed by Kanghong biology, which has full independent intellectual property rights This product can effectively combine with VEGF in blood vessels and tissues, and block the signal transmission mediated by VEGF to promote the sprouting and growth of new blood vessels Xinhua Pharmaceutical announced in the evening of May 16 that the company received the approval document for drug registration of fasudil hydrochloride injection approved and issued by the State Food and drug administration The data shows that the annual sales volume of fasudil hydrochloride injection in China is about 400 million yuan Fasudil hydrochloride has become a drug to improve and prevent cerebral vasospasm and cerebral ischemia after subarachnoid hemorrhage Beijing New Pharmaceutical Co., Ltd announced in the evening of May 14 that the company received the registration approval document of rosuvastatin calcium dispersible tablets (specification: 10mg) approved and issued by the State Drug Administration Rosuvastatin calcium dispersible tablets disintegrated rapidly when exposed to water, especially for the elderly or patients with dysphagia, so as to improve the compliance of patients Fuan Pharmaceutical Group Ningbo Tianheng Pharmaceutical Co., Ltd., a subsidiary of Fuan Pharmaceutical Group, recently received the registration approval of tropisetron hydrochloride injection with the specification of 5ml: 5mg issued by the State Drug Administration, which was recently announced by Fuan Pharmaceutical Group The main indication of tropisetron hydrochloride injection is to prevent and treat nausea and vomiting caused by cancer chemotherapy Changshan Pharmaceutical Co., Ltd announced in the evening of May 13 that the company had recently received the drug registration approval for enoxaparin sodium injection approved and issued by the State Food and drug administration The main functions of the drug are to prevent the formation of deep vein thrombosis and pulmonary embolism; to treat the formed vein thrombosis; to prevent the formation of thrombus during cardiopulmonary bypass during hemodialysis; to treat unstable angina pectoris and non-Q wave myocardial infarction The acquisition of registration documents enriches the company's core product categories and optimizes the product structure The drug will have a positive impact on the company's performance Kelun pharmaceutical Sichuan Kelun Pharmaceutical Co., Ltd recently obtained the approval of drug registration for the chemical "moxifloxacin hydrochloride sodium chloride injection" approved and issued by the State Drug Administration Moxifloxacin hydrochloride and sodium chloride injection are mainly used to treat adult upper and lower respiratory tract infections, skin and soft tissue infections, complex abdominal infections, including mixed bacterial infections Haichen pharmaceutical Nanjing Haichen Pharmaceutical Co., Ltd recently received the approval of drug registration issued by the State Drug Administration for the improvement of various symptoms induced by cerebral infarction sequelae, cerebral hemorrhage sequelae and cerebral arteriosclerosis.